Hologic, Inc. (NASDAQ:HOLX) Shares Bought by Wealthfront Advisers LLC

Wealthfront Advisers LLC lifted its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 300.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 45,083 shares of the medical equipment provider's stock after purchasing an additional 33,833 shares during the period. Wealthfront Advisers LLC's holdings in Hologic were worth $2,785,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Leo Wealth LLC boosted its position in shares of Hologic by 25.5% in the 1st quarter. Leo Wealth LLC now owns 7,505 shares of the medical equipment provider's stock valued at $464,000 after purchasing an additional 1,527 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Hologic by 11.1% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 49,209 shares of the medical equipment provider's stock valued at $3,040,000 after purchasing an additional 4,918 shares during the period. Edgestream Partners L.P. acquired a new position in Hologic in the 1st quarter valued at about $1,038,000. MQS Management LLC acquired a new position in Hologic in the 1st quarter valued at about $394,000. Finally, Stephens Investment Management Group LLC increased its position in Hologic by 2.3% in the 1st quarter. Stephens Investment Management Group LLC now owns 764,931 shares of the medical equipment provider's stock valued at $47,250,000 after acquiring an additional 17,396 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Trading Down 0.0%

Shares of HOLX traded down $0.03 during trading hours on Friday, hitting $63.99. The stock had a trading volume of 1,582,099 shares, compared to its average volume of 2,386,077. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. The firm has a market cap of $14.26 billion, a P/E ratio of 27.00, a P/E/G ratio of 2.35 and a beta of 0.55. The company's fifty day simple moving average is $62.46 and its 200 day simple moving average is $63.18. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The business's quarterly revenue was down 1.2% on a year-over-year basis. During the same period last year, the company posted $1.03 EPS. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Buying and Selling at Hologic

In related news, Director Martin D. Madaus acquired 5,445 shares of the business's stock in a transaction on Wednesday, May 7th. The shares were bought at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the transaction, the director directly owned 5,445 shares of the company's stock, valued at $300,781.80. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.88% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on HOLX. Mizuho boosted their target price on Hologic from $65.00 to $70.00 and gave the stock an "outperform" rating in a research report on Wednesday. Morgan Stanley reduced their target price on Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Raymond James Financial reaffirmed an "outperform" rating and issued a $71.00 target price (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and upped their target price for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Finally, Evercore ISI upped their target price on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Hologic presently has a consensus rating of "Hold" and an average price target of $77.33.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.